NCT06723405Phase 2Completed

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Study sponsor: Evommune, Inc. · EVMN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2025-11-17Actual
Enrollment · participants71Actual
Source updated2025-12-04Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

60 participants (planned)

+ After

71 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Nov 2025

+ After

17 Nov 2025

Recruitment status changed

− Before

Active not recruiting

+ After

Completed

Check registry source